Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis and Molecular Partners’ Ensovibep Flunks In ACTIV-3 In Hospitalized COVID-19 Patients

Hopes Turn To Non-Hospitalized Patients

Executive Summary

Ensovibep failed to meet thresholds for continued enrollment in the large NIH Phase III trial, forcing Novartis and Molecular to home in on the early COVID-19 setting instead.

You may also be interested in...



COVID-19: US ACTIV Study Expands To Include Three Repurposed Drugs

Efforts to find new uses for old drugs in COVID-19 patients are gathering pace.

Novartis COVID-19 Therapy Could Overcome Escape Variant Problem

The DARPin candidate will not gain emergency approval before early 2022, but its likely ability to sustain efficacy regardless of SARS-CoV-2 mutations could be valuable as new variants emerge.

SynAct Surveys Its Options As Rheumatoid Arthritis Asset Succeeds At Phase II

The company’s lead candidate, AP1189, has shown promise in a mid-stage rheumatoid arthritis study, sparking plans for an imminent strategic business collaboration. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC145425

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel